Commercial Bank OF Ceylon PLC Pharmaceutical Import Profile — Sri Lanka (DGFT 2022–2026)

Name: Commercial Bank OF Ceylon PLC Pharmaceutical Import Records from India — 3 Products, $520.7K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Commercial Bank OF Ceylon PLC — Pharmaceutical Importer Profile (2026) | 3 Products, $520.7K Trade | TransData Nexus

Commercial Bank OF Ceylon PLC

Pharmaceutical Importer · Sri Lanka · Cardiovascular Focus · $520.7K Total Trade · DGFT Verified

Commercial Bank OF Ceylon PLC is a pharmaceutical importer based in Sri Lanka with a total trade value of $520.7K across 3 products in 3 therapeutic categories. Based on 26 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Commercial Bank OF Ceylon PLC sources from 19 verified Indian suppliers, with United Biotech Private Limited accounting for 43.8% of imports.

Commercial Bank OF Ceylon PLC — Import Portfolio & Supplier Network

Commercial Bank OF Ceylon PLC import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Commercial Bank OF Ceylon PLC?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
United Biotech Private Limited	$1.9M	182	43.8%
Torrent Pharmaceuticals Limited	$1.1M	42	25.8%
Nibblen Life Sciences Private Limited

What Formulations Does Commercial Bank OF Ceylon PLC Import?

Formulation	Value	Ships
Dilzem sr tablet(diltiazem	$150.0K	3
Mosid mt 5 tablet(mosapride citrate 5MG)	$150.0K	3
Pharma product-tiplab 100(labetalol	$98.0K	4
Telday 80 tablet (telmisartan 80 MG)	$87.1K	2
Pharma product-menem 1.0(meropenem	$74.4K	3
Cefoprit 750,cefuroxime for injection750mg,b/n:cfdh3a22,cfdh3a23,md:08/23	$64.6K	2
Dilzem 60 tablet(diltiazem hcl 60MG	$62.7K	4
Cefoprit750,cefuroxime for injection	$59.9K	2
Cefoprit 750,cefuroxime for injection 750mgbatch no:cfdh3a15/cfdh3a16, manufacturing dt:08/2023,exp	$53.9K	2
Nexpro 20 tablet (esomeprazole	$50.0K	1
(others)telday 40 tablet(telmisartan	$50.0K	1
Azukon mr 30 tablet (gliclazide 30 MG	$50.0K	1
Nervex bt-softgelatin capsules(mecobalamin, ala,benfotiamine,b6+folic acid+inositol) & free units qty:1255 as per	$50.0K	1
Thymogam 250MG (antithymocyte globulin -equine)	$49.1K	1
Vaccine for human medicine (single vaccine for tetanus)tetanus vaccine 1	$45.4K	1

Commercial Bank OF Ceylon PLC imports 224 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Diltiazem	Cardiovascular	$245.9K	8	1.4%	19
2	Glucosamine	Nutritional Supplements	$179.5K	10	1.4%	14
3	Ceftazidime	Advanced Antibiotics	$95.3K	8	0.9%	14

Commercial Bank OF Ceylon PLC imports 3 pharmaceutical products across 3 categories into Sri Lanka totaling $520.7K.

Commercial Bank OF Ceylon PLC — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Commercial Bank of Ceylon PLC (CBC) is a prominent licensed commercial bank in Sri Lanka, established in 1920 and incorporated as a public limited company in 1969. Headquartered in Colombo, CBC operates a network of 291 branches and approximately 948 ATMs across Sri Lanka, making it the largest private bank in the country in terms of net worth and capital.

While primarily a financial institution, CBC has diversified its operations to include pharmaceutical importation. Between 2022 and 2026, the bank imported finished pharmaceutical formulations from India, totaling $521,000 across 26 shipments. These imports encompassed three therapeutic categories: cardiovascular, nutritional supplements, and advanced antibiotics. The top five products imported were Diltiazem, Glucosamine, and Ceftazidime, with Diltiazem accounting for the largest share at $246,000.

2Distribution Network

CBC's pharmaceutical distribution network is integrated within its extensive banking infrastructure. The bank's 291 branches across Sri Lanka serve as points of contact for pharmaceutical distribution, leveraging existing logistics capabilities to manage the import and distribution of pharmaceutical products. This integration allows for efficient handling and delivery of imported pharmaceuticals to various regions within the country.

3Industry Role

In Sri Lanka's pharmaceutical supply chain, CBC functions as a pharmaceutical importer and distributor. By importing finished pharmaceutical formulations from India, the bank supplements the local market with essential medicines, particularly in therapeutic areas such as cardiovascular health, nutritional supplements, and advanced antibiotics. This role positions CBC as a key player in enhancing the availability and accessibility of critical pharmaceutical products in Sri Lanka.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Commercial Bank OF Ceylon PLC

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

CBC's pharmaceutical sourcing strategy exhibits a high degree of concentration, with the top five products imported accounting for 100% of the total import value. This indicates a focused approach to procurement, potentially streamlining operations and ensuring consistency in product quality. However, such concentration also introduces risks associated with supply chain disruptions. The reliance on a limited number of products may expose CBC to vulnerabilities if there are issues with supply continuity or regulatory changes affecting these specific products.

2Supply Chain Resilience

The resilience of CBC's pharmaceutical supply chain is closely tied to its sourcing strategy. With a concentrated portfolio, the bank's supply chain may face challenges if disruptions occur with its primary suppliers. The limited number of suppliers and formulations imported suggests a need for diversification to mitigate potential risks. Additionally, the bank's logistics capabilities, integrated within its banking network, provide a robust framework for managing imports; however, reliance on a single distribution network may limit flexibility in responding to supply chain disruptions.

3Strategic Implications

Importing Pharmaceuticals into Sri Lanka — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Sri Lanka

1Regulatory Authority & Framework

The National Medicines Regulatory Authority (NMRA) is the primary regulatory body overseeing pharmaceutical imports in Sri Lanka. The NMRA enforces regulations to ensure the safety, efficacy, and quality of medicines entering the country. Key legislation governing pharmaceutical imports includes the Medicines (Pricing Mechanism for Medicines) Regulations, which establish guidelines for pricing and importation procedures. The NMRA also provides guidelines on import control, specifying the requirements for importing pharmaceutical products and raw materials. (nmra.gov.lk)

2Import Licensing & GMP

Import licensing is mandatory for all pharmaceutical products entering Sri Lanka. Importers must obtain approval from the NMRA before distributing or selling any pharmaceutical product. Applications for import licenses should be submitted at least twelve weeks in advance to avoid delays. Additionally, importers are required to submit price details through a specified format provided by the NMRA. Evidence of previous importation and participation in tenders may also be required.

3Quality & Labeling

Commercial Bank OF Ceylon PLC — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

CBC's focus on importing pharmaceutical products in the cardiovascular, nutritional supplements, and advanced antibiotics categories aligns with the significant demand for these medications in Sri Lanka. The high import values of Diltiazem and Glucosamine indicate a substantial market need for these products. By concentrating on these therapeutic areas, CBC addresses critical health concerns prevalent in the country, positioning itself as a key supplier of essential medicines.

2Sourcing Profile

CBC's sourcing strategy is centered on importing finished pharmaceutical formulations from India, with a particular emphasis on generic drugs. This approach allows the bank to provide cost-effective medications to the Sri Lankan market, ensuring affordability and accessibility. The focus on specific therapeutic categories suggests a targeted procurement strategy aimed at meeting the most pressing health needs in the country.

3Market Positioning

Through its pharmaceutical importation activities, CBC serves multiple segments of the Sri Lankan market, including retail pharmacies, hospitals, and government tenders. The bank's extensive branch network facilitates the distribution of imported pharmaceuticals to various healthcare providers, ensuring widespread availability. By supplying essential medicines, CBC plays a crucial role in supporting the healthcare infrastructure and meeting the needs of patients across the country.

Seller's Guide — How to Become a Supplier to Commercial Bank OF Ceylon PLC

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with CBC, particularly those offering products in the cardiovascular, nutritional supplements, and advanced antibiotics categories. The bank's concentrated sourcing pattern indicates a preference for stable and predictable supply chains, which new suppliers can align with by demonstrating reliability and compliance with Sri Lankan regulatory standards. Diversifying the supplier base could also enhance CBC's supply chain resilience and mitigate potential risks associated with over-reliance on a limited number of suppliers.

2Requirements & Qualifications

Indian exporters seeking to supply pharmaceutical products to CBC and the Sri Lankan market must adhere to the NMRA's regulatory requirements. This includes obtaining the necessary import licenses, ensuring compliance with Good Manufacturing Practice (GMP) standards recognized by the NMRA, and providing batch release certificates and material safety data sheets for the products. Additionally, products must meet labeling requirements, including displaying the Maximum Retail Price and the name and address of the local MAH or importer.

3How to Approach

Frequently Asked Questions — Commercial Bank OF Ceylon PLC

What products does Commercial Bank OF Ceylon PLC import from India?

Commercial Bank OF Ceylon PLC imports 3 pharmaceutical products across 3 categories. Top imports: Diltiazem ($245.9K), Glucosamine ($179.5K), Ceftazidime ($95.3K).

Who supplies pharmaceuticals to Commercial Bank OF Ceylon PLC from India?

Commercial Bank OF Ceylon PLC sources from 19 verified Indian suppliers. The primary supplier is United Biotech Private Limited (43.8% of imports, $1.9M).

What is Commercial Bank OF Ceylon PLC's total pharmaceutical import value?

Commercial Bank OF Ceylon PLC's total pharmaceutical import value from India is $520.7K, based on 26 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Commercial Bank OF Ceylon PLC focus on?

Commercial Bank OF Ceylon PLC imports across 3 categories. The largest: Cardiovascular (47.2%), Nutritional Supplements (34.5%), Advanced Antibiotics (18.3%).

Get Full Commercial Bank OF Ceylon PLC Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.